These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9365997)

  • 21. Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
    Greenbaum L; Goldwurm S; Zozulinsky P; Lifschytz T; Cohen OS; Yahalom G; Cilia R; Tesei S; Asselta R; Inzelberg R; Kohn Y; Hassin-Baer S; Lerer B
    J Mol Neurosci; 2013 Oct; 51(2):380-8. PubMed ID: 23666822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia: treatment with aripiprazole.
    Kang NR; Kim MD
    Clin Psychopharmacol Neurosci; 2011 Apr; 9(1):1-8. PubMed ID: 23430384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats.
    Pereira RP; Fachinetto R; de Souza Prestes A; Wagner C; Sudati JH; Boligon AA; Athayde ML; Morsch VM; Rocha JB
    J Neural Transm (Vienna); 2011 Nov; 118(11):1547-57. PubMed ID: 21476069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
    Caroff SN; Hurford I; Lybrand J; Campbell EC
    Neurol Clin; 2011 Feb; 29(1):127-48, viii. PubMed ID: 21172575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
    J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats.
    Colpo G; Trevisol F; Teixeira AM; Fachinetto R; Pereira RP; Athayde ML; Rocha JB; Burger ME
    Neurotox Res; 2007 Oct; 12(3):171-80. PubMed ID: 17967741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse effects of atypical antipsychotics : differential risk and clinical implications.
    Haddad PM; Sharma SG
    CNS Drugs; 2007; 21(11):911-36. PubMed ID: 17927296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
    Pierre JM
    Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.
    Leo RJ; Regno PD
    Prim Care Companion J Clin Psychiatry; 2000 Dec; 2(6):194-204. PubMed ID: 15014629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
    Naidu PS; Singh A; Kulkarni SK
    Psychopharmacology (Berl); 2003 Jun; 167(4):418-23. PubMed ID: 12669184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
    Naidu PS; Singh A; Kulkarni SK
    Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.
    Caligiuri MR; Jeste DV; Lacro JP
    Drugs Aging; 2000 Nov; 17(5):363-84. PubMed ID: 11190417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of tardive dyskinesia and tardive dystonia.
    Simpson GM
    J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of tardive dyskinesia.
    Egan MF; Apud J; Wyatt RJ
    Schizophr Bull; 1997; 23(4):583-609. PubMed ID: 9365997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.